CCL3+ neutrophil signature predicts response to neoadjuvant toripalimab plus chemotherapy in patients with hypopharyngeal squamous cell carcinoma: A phase II trial
The efficacy of nCIT in HPSCC is predetermined by a baseline immune architecture orchestrated by a CCL3+ neutrophil subset. The Neu_CCL3 gene signature is a promising, clinically translatable biomarker that can fill a critical gap in precision immunotherapy for HPSCC.
Authors
- Xia Liu (ORCID: https://orcid.org/0000-0002-9209-0562)
- Hengmin Tao
- Zhong Shen (ORCID: https://orcid.org/0000-0003-4724-3803)
- Peihang Jing
- S Zhou
- Zhenghua Lv
- Yumei Wei
- Wei Xu
- Zhichao Liu
- Juke Ma
- Fang Chen
Institutions
- Shandong Provincial Hospital (CN)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-4096
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00